{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:16Z","timestamp":1793725696848,"version":"4.6.1"},"reference-count":9,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,11,22]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Ischaemic optic neuropathy (ION) is a rare but vision-threatening complication recently linked to GLP-1 receptor agonists, particularly semaglutide. Using over 30\u2009million reports from the FDA Adverse Event Reporting System (2017\u20132024), we evaluated formulation- and sex-specific associations. Among 31\u2009774 semaglutide cases, Wegovy demonstrated the strongest signal for ION (reporting odds ratio (ROR)=74.89) compared with Ozempic (ROR=18.81). Sex-stratified analyses showed higher odds in men (ROR=116.37), and multivariable regression confirmed greater risk with Wegovy versus Ozempic (adjusted OR (AOR)=4.74) and in men versus women (AOR=3.33). These findings highlight a potential dose-dependent safety concern that warrants urgent prospective evaluation to guide prescribing and regulatory policy.<\/jats:p>","DOI":"10.1136\/bjo-2025-328483","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:55:05Z","timestamp":1773186905000},"page":"732-735","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4603-826X","authenticated-orcid":false,"given":"Moiz","family":"Lakhani","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-7033","authenticated-orcid":false,"given":"Abdullah","family":"Al-Ani","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Ophthalmology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"B\u00e9nard-S\u00e9guin","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Ophthalmology, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6738-7225","authenticated-orcid":false,"given":"Edward","family":"Margolin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"2026062202151368000_110.7.732.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1413352"},{"key":"2026062202151368000_110.7.732.2","unstructured":"FDA adverse event reporting system (FAERS) public dashboard. US Food and Drug Administration; 2023. Available: https:\/\/www.fda.gov\/drugs\/fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard [Accessed 7 Dec 2023]."},{"key":"2026062202151368000_110.7.732.3","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"2026062202151368000_110.7.732.4","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: A systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026062202151368000_110.7.732.5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"2026062202151368000_110.7.732.6","unstructured":"Kommu S , Whitfield P . Semaglutide. In: Statpearls. StatPearls Publishing, 2025."},{"key":"2026062202151368000_110.7.732.7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"2026062202151368000_110.7.732.8","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.2026","article-title":"Prescription Fills for Semaglutide Products by Payment Method","volume":"5","author":"Scannell","year":"2024","journal-title":"JAMA Health Forum"},{"key":"2026062202151368000_110.7.732.9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57232","article-title":"Longitudinal Analysis of Obesity Drug Use and Public Awareness","volume":"8","author":"Berning","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-328483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T09:15:51Z","timestamp":1782119751000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-328483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bjo-2025-328483"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-328483","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]}}}